Science Explorer Back to mapMap
Discussion
Researcher · Sumitomo Dainippon Pharma (Japan) · Japan

Keizo Matsushita

Keizo Matsushita publishes mostly in Molecular Biology, Cellular and Molecular Neuroscience and Aerospace Engineering, on topics such as Retinal Development and Disorders, Neuroscience and Neural Engineering and Genomics and Chromatin Dynamics.

OpenAlex
World rank
#2,178,450
of 7,710,434 ranked researchers
Rank in Japan
#41,187
of 383,136
Works
17
Citations
710
Citations per work
41.8
h-index
8
i10-index 7Top 87% in Molecular Biology
Keizo Matsushita

What does Keizo Matsushita research?

Keizo Matsushita's work is mostly in Biochemistry, Genetics and Molecular Biology (71%), Neuroscience (22%), Medicine (5%).

Life Sciences: 16 works · 92.7% of their workBiochemistry, Genetics and Molecular Biology: 12 works · 70.7% of their workMolecular Biology: 12 works · 68.3% of their workMolecular Medicine: 0 works · 2.4% of their workNeuroscience: 4 works · 22.0% of their workCellular and Molecular Neuroscience: 4 works · 22.0% of their workHealth Sciences: 1 works · 4.8% of their workMedicine: 1 works · 4.8% of their workOncology: 0 works · 2.4% of their workPharmacology: 0 works · 2.4% of their workPhysical Sciences: 0 works · 2.4% of their workEngineering: 0 works · 2.4% of their workAerospace Engineering: 0 works · 2.4% of their workTHEIR WORKKeizo Matsushita17works
Life Sciences93%Physical Sciences2%Health Sciences5%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1270.7%
    2. Neuroscience422.0%
    1. Medicine14.8%
    1. Engineering02.4%
  1. 1Molecular Biology68% of their works
  2. 2Cellular and Molecular Neuroscience22% of their works
  3. 3Aerospace Engineering2% of their works
  4. 4Oncology2% of their works
  5. 5Pharmacology2% of their works
  6. 6Molecular Medicine2% of their works

Research topics

Which keywords describe Keizo Matsushita's research?

The keywords of their largest research topics: Gene Therapy, Retinitis Pigmentosa, Electrode Arrays, Neural Stimulation, Chromatin, Transcription, Ribosome and Translation.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 16 words, with their numbers
  1. Gene Therapy81 topic
  2. Retinitis Pigmentosa81 topic
  3. Electrode Arrays71 topic
  4. Neural Stimulation71 topic
  5. Chromatin51 topic
  6. Transcription51 topic
  7. Ribosome41 topic
  8. Translation41 topic
  9. DNA Structure31 topic
  10. G-Quadruplexes31 topic
  11. Induced Pluripotent Stem Cells31 topic
  12. Pluripotent Stem Cells31 topic
  13. Channelrhodopsin21 topic
  14. Genome Engineering21 topic
  15. Optogenetics21 topic
  16. RNA-Guided21 topic

Where does Keizo Matsushita work?

Keizo Matsushita's main affiliation in the publication record is Sumitomo Dainippon Pharma (Japan), Japan.

How many publications and citations does Keizo Matsushita have?

OpenAlex counts 17 works and 710 citations for Keizo Matsushita, an h-index of 8, ranking #2,178,450 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Keizo Matsushita. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.